Cancer Therapy

Phase II trial of AP23573 initiated in hormone-refractory prostate cancer

Published in Drug Week, June 10th, 2005

Ariad Pharmaceuticals, Inc., (ARIA) announced initiation of enrollment of patients with prostate cancer who have become refractory to standard hormone therapy in a multicenter phase II clinical trial of its novel mTOR inhibitor, AP23573, as a single agent.

Prostate cancer is the most common cancer diagnosis in men other than skin cancer. Progression to hormone-refractory disease is associated with a very poor prognosis, and current therapeutic options are severely limited.

This non-randomized study will evaluate the clinical benefit of AP23573 in well-characterized prostate cancer patients. Up to approximately 35 patients will be enrolled in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry